Reported 5 days ago
Novo Nordisk reported a significant earnings miss, attributed to competitor pressures and internal leadership changes, causing their stock to plummet. CFO Karsten Munk Knudsen emphasized that cash payments will increasingly constitute a major part of the Wegovy business, noting that 10% of Wegovy patients in the U.S. are already paying cash. Despite skepticism regarding the viability of this cash market strategy, Knudsen maintains optimism about its future potential.
Source: YAHOO